CL2013000768A1 - Composicion farmaceutica que comprende un compuesto derivado de (6s)-6-(2-hidroxi-2-metilpropil)-6-fenil-3-{(1s)-1-[4-(2-oxo-1,2-dihidropiridin-4-il)fenil]etil}-1,3-oxazin-2-ona y un segundo agente terapéutico; y su uso para prevenir o retrasar un trastorno asociado a diabetes mellitus 2 o tolerancia alterada a la glucosa. - Google Patents

Composicion farmaceutica que comprende un compuesto derivado de (6s)-6-(2-hidroxi-2-metilpropil)-6-fenil-3-{(1s)-1-[4-(2-oxo-1,2-dihidropiridin-4-il)fenil]etil}-1,3-oxazin-2-ona y un segundo agente terapéutico; y su uso para prevenir o retrasar un trastorno asociado a diabetes mellitus 2 o tolerancia alterada a la glucosa.

Info

Publication number
CL2013000768A1
CL2013000768A1 CL2013000768A CL2013000768A CL2013000768A1 CL 2013000768 A1 CL2013000768 A1 CL 2013000768A1 CL 2013000768 A CL2013000768 A CL 2013000768A CL 2013000768 A CL2013000768 A CL 2013000768A CL 2013000768 A1 CL2013000768 A1 CL 2013000768A1
Authority
CL
Chile
Prior art keywords
phenyl
oxazin
dihydropyridine
methylpropyl
oxo
Prior art date
Application number
CL2013000768A
Other languages
English (en)
Inventor
Bradfor S Hamilton
Thomas Rauch
Manami Tsutsumi
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44903228&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000768(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2013000768A1 publication Critical patent/CL2013000768A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2013000768A 2010-11-02 2013-03-20 Composicion farmaceutica que comprende un compuesto derivado de (6s)-6-(2-hidroxi-2-metilpropil)-6-fenil-3-{(1s)-1-[4-(2-oxo-1,2-dihidropiridin-4-il)fenil]etil}-1,3-oxazin-2-ona y un segundo agente terapéutico; y su uso para prevenir o retrasar un trastorno asociado a diabetes mellitus 2 o tolerancia alterada a la glucosa. CL2013000768A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40924110P 2010-11-02 2010-11-02

Publications (1)

Publication Number Publication Date
CL2013000768A1 true CL2013000768A1 (es) 2013-10-11

Family

ID=44903228

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000768A CL2013000768A1 (es) 2010-11-02 2013-03-20 Composicion farmaceutica que comprende un compuesto derivado de (6s)-6-(2-hidroxi-2-metilpropil)-6-fenil-3-{(1s)-1-[4-(2-oxo-1,2-dihidropiridin-4-il)fenil]etil}-1,3-oxazin-2-ona y un segundo agente terapéutico; y su uso para prevenir o retrasar un trastorno asociado a diabetes mellitus 2 o tolerancia alterada a la glucosa.

Country Status (16)

Country Link
US (3) US20120277149A1 (es)
EP (1) EP2635268A1 (es)
JP (1) JP2013540801A (es)
KR (1) KR20130137628A (es)
CN (1) CN103179960A (es)
AR (1) AR083679A1 (es)
AU (1) AU2011325286B2 (es)
BR (1) BR112013010021A2 (es)
CA (1) CA2813671A1 (es)
CL (1) CL2013000768A1 (es)
EA (1) EA201300522A1 (es)
MX (1) MX2013004699A (es)
PH (1) PH12013500808A1 (es)
TW (1) TW201304783A (es)
UY (1) UY33700A (es)
WO (1) WO2012059416A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5451611B2 (ja) 2007-07-26 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックインヒビター
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
CA2708303A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
TW200934490A (en) 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
WO2009094169A1 (en) 2008-01-24 2009-07-30 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8598160B2 (en) 2008-02-15 2013-12-03 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EP2291370B1 (en) 2008-05-01 2013-11-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
KR20110002492A (ko) 2008-05-01 2011-01-07 비타이 파마슈티컬즈, 인코포레이티드 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
US8846668B2 (en) 2008-07-25 2014-09-30 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2729993A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
WO2010011314A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
JP5679997B2 (ja) 2009-02-04 2015-03-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
UA109255C2 (ru) 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
WO2011011123A1 (en) 2009-06-11 2011-01-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
EP2496589B1 (en) 2009-11-05 2014-03-05 Boehringer Ingelheim International GmbH Novel chiral phosphorus ligands
EP2576570A1 (en) 2010-05-26 2013-04-10 Boehringer Ingelheim International GmbH 2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives
EP2582698B1 (en) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
WO2011161128A1 (en) 2010-06-25 2011-12-29 Boehringer Ingelheim International Gmbh Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
CA2813671A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
UY35065A (es) * 2012-10-08 2014-05-30 Lg Life Sciences Ltd Fármaco combinado que comprende gemigliptina y metformina y método para su preparación
WO2014084433A1 (ko) * 2012-11-30 2014-06-05 경상대학교 산학협력단 퍼옥시좀 증식인자 활성화 수용체 델타 작용물질을 유효성분으로 함유하는 심근경색후 심근상처치유 촉진용 조성물
KR101863583B1 (ko) * 2014-03-19 2018-06-01 경북대학교병원 게미글립틴을 유효성분으로 함유하는 혈관성 질환의 예방 또는 치료용 약학적 조성물
WO2017106112A1 (en) * 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Methods of preventing or treating hypoglycemia by administering a gpr119 agonist
CN109640993B (zh) * 2016-08-12 2021-07-09 诺麦塔制药有限公司 包含阿莫地喹及抗糖尿病药物作为有效成分的用于预防或治疗糖尿病的药学组合物
WO2020071865A1 (ko) * 2018-10-04 2020-04-09 한미약품 주식회사 글루카곤 및 이를 포함하는 조합물의 치료학적 용도
WO2024055932A1 (zh) * 2022-09-13 2024-03-21 亚宝药业集团股份有限公司 氮杂环化合物、其药物组合物和用于预防和/或治疗疾病的用途
US20260130933A1 (en) * 2022-10-05 2026-05-14 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical composition for prevention or treatment of nephropathy and/or diabetes mellitus, comprising enavogliflozin

Family Cites Families (228)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3378587A (en) 1963-03-14 1968-04-16 Du Pont 3, 3'-diaminomethyl-1, 1'-biadamantane
NL127995C (es) 1963-12-20 Geigy Ag J R
US3341538A (en) 1965-06-18 1967-09-12 Geigy Chem Corp Certain 2, 6-methano-3-benzazocines
DE1801556A1 (de) 1968-10-05 1970-05-21 Huels Chemische Werke Ag Verfahren zur Herstellung von substituierten Hexahydropyrimidinonen-(2)
GB1304175A (es) 1969-03-31 1973-01-24
US3681349A (en) 1970-03-05 1972-08-01 Morton Norwich Products Inc 1-(substituted benzyl) tetrahydro-2-(1h) pyrimidones
US4043927A (en) 1972-03-07 1977-08-23 Sun Ventures, Inc. Friction or tractive drive containing ethers of adamantanes
DE2338369A1 (de) 1973-07-26 1975-02-13 Schering Ag Mikrobiologische hydroxylierung von 2,6-methano-3-benzazocinen
US4009171A (en) 1974-02-21 1977-02-22 Sterling Drug Inc. N-acylated-11-oxygenated-2,6-methano-3-benzazocine intermediates
US4136162A (en) 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
US4136145A (en) 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
GB1513961A (en) 1975-02-25 1978-06-14 Acf Chemiefarma Nv 6,7-benzomorphans method for their preparation and intermediates
US4108857A (en) 1975-08-18 1978-08-22 Sterling Drug Inc. Imidazolylmethyl methanobenzazocines
US5393735A (en) 1990-08-09 1995-02-28 Rohm And Haas Company Herbicidal glutarimides
CA2023492A1 (en) 1989-08-31 1991-03-01 Barry Clifford Lange Herbicidal glutarimides
US5098916A (en) 1990-03-29 1992-03-24 G. D. Searle & Co. Propanobicyclic amine derivatives for cns disorders
EP0454444A1 (en) 1990-04-24 1991-10-30 Nissan Chemical Industries Ltd. Glutarimide derivatives and herbicides
US5089506A (en) 1990-04-30 1992-02-18 G. D. Searle & Co. Ethanobicyclic amine derivatives for cns disorders
US5215992A (en) 1990-04-30 1993-06-01 G. D. Searle & Co. Ethanobicyclic amine derivatives for CNS disorders
DK204291D0 (da) 1991-12-20 1991-12-20 Novo Nordisk As Heterocykliske forbindelser deres fremstilling og anvendelse
CA2049244A1 (en) 1990-08-16 1992-02-17 Steven H. Christiansen Process for absorption of sulfur compounds from fluids using heterocyclic compounds having at least one ring nitrogen atom
ATE122673T1 (de) 1990-10-10 1995-06-15 Schering Corp Pyridin- und pyridin-n-oxid-derivate von diarylmethyl- piperidinen oder piperazinen, deren zusammensetzungen und anwendung.
GB9023583D0 (en) 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
US5610294A (en) 1991-10-11 1997-03-11 The Du Pont Merck Pharmaceutical Company Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
KR100268694B1 (ko) 1991-10-11 2000-10-16 미리암 디. 메코너헤이, 블레어큐. 퍼거슨 레트로바이러스 프로테아제 억제제로 유용한 시클릭 우레아 및 유사체
HU220601B1 (hu) 1992-04-30 2002-03-28 Taiho Pharmaceutical Co. Ltd. Fenoxi-alkil-oxazolidin-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
GB9225377D0 (en) 1992-12-04 1993-01-27 Ici Plc Herbicides
HU224548B1 (hu) 1993-04-07 2005-10-28 Taiho Pharmaceutical Co. Ltd. Tiazolidinszármazékok és ezeket tartalmazó gyógyszerkészítmények, valamint eljárás előállításukra
TW280812B (es) 1993-07-02 1996-07-11 Bayer Ag
EP0640594A1 (en) 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
DE19500118A1 (de) 1994-05-18 1995-11-23 Bayer Ag Substituierte Diazacyclohexandi(thi)one
WO1996014297A1 (en) 1994-11-04 1996-05-17 Sumitomo Pharmaceuticals Company, Limited Novel lactam derivatives
FR2729954B1 (fr) 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
US5780466A (en) 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
GB9510459D0 (en) 1995-05-24 1995-07-19 Zeneca Ltd Bicyclic amines
US5776959A (en) 1995-06-05 1998-07-07 Washington University Anticonvulsant and anxiolytic lactam and thiolactam derivatives
GB9517622D0 (en) 1995-08-29 1995-11-01 Univ Edinburgh Regulation of intracellular glucocorticoid concentrations
JPH09151179A (ja) 1995-11-30 1997-06-10 Canon Inc 光学活性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた液晶装置及び表示方法
WO1997036605A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2262502C (en) 1996-07-31 2002-11-26 Nikken Chemicals Co., Ltd. 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and pharmaceutical composition containing the same
US6794390B2 (en) 1996-08-02 2004-09-21 Cv Therapeutics, Inc. Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
GB9623944D0 (en) 1996-11-15 1997-01-08 Zeneca Ltd Bicyclic amine derivatives
US6159990A (en) 1997-06-18 2000-12-12 Synaptic Pharmaceutical Corporation Oxazolidinones as α1A receptor antagonists
JP2002505683A (ja) 1997-06-18 2002-02-19 シナプティック・ファーマスーティカル・コーポレーション 複素環置換されたピペリジン類及びその使用
DE19731784A1 (de) 1997-07-24 1999-02-04 Bayer Ag Substituierte N-Aryl-N-thioxocarbonyl-sulfonamide
GB9715892D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
US5936124A (en) 1998-06-22 1999-08-10 Sepacor Inc. Fluoxetine process from benzoylpropionic acid
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
DE19918725A1 (de) 1999-04-24 2000-10-26 Bayer Ag Substituierte N-Cyano-sulfonsäureanilide
DE19929348A1 (de) 1999-06-26 2000-12-28 Bayer Ag Verfahren zur Herstellung von 2-Heterocyclylmethyl-benzoesäurederivaten
US7256005B2 (en) 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
WO2001013917A1 (en) 1999-08-26 2001-03-01 Bristol-Myers Squibb Company Npy antagonists: spiroisoquinolinone derivatives
JP2003522739A (ja) 1999-12-17 2003-07-29 シェーリング コーポレイション 選択的ニューロキニンアンタゴニスト
US6436928B1 (en) 1999-12-17 2002-08-20 Schering Corporation Selective neurokinin antagonists
WO2001055063A1 (en) 2000-01-25 2001-08-02 Idemitsu Petrochemical Co., Ltd. Novel bisadamantane compounds, process for preparing the same, and novel biadamantane derivatives
GB0003397D0 (en) 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
DE10034623A1 (de) 2000-07-17 2002-01-31 Bayer Ag Heterocyclisch substituierte Pyridine als Cytokin-Inhibitoren
DE10034800A1 (de) 2000-07-18 2002-01-31 Bayer Ag Substituierte Benzostickstoffheterocyclen
DE10034803A1 (de) 2000-07-18 2002-01-31 Bayer Ag Substituierte Sulfonsäureanilide
DE10035927A1 (de) 2000-07-21 2002-03-07 Asta Medica Ag Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
DE10035928A1 (de) 2000-07-21 2002-03-07 Asta Medica Ag Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
DE10035908A1 (de) 2000-07-21 2002-03-07 Asta Medica Ag Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
US6559163B2 (en) 2000-08-16 2003-05-06 Neurogen Corporation 2,4-substituted quinoline derivatives
US7294637B2 (en) 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
EP1318988A2 (en) 2000-09-11 2003-06-18 Sepracor, Inc. Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission)
JP2002179572A (ja) 2000-10-06 2002-06-26 Nikken Chem Co Ltd アレルギー性眼疾患治療剤
US6841671B2 (en) 2000-10-26 2005-01-11 Pfizer Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
US20030143668A1 (en) 2001-06-18 2003-07-31 National Institute Of Advanced Industrial Guanosine triphosphate-binding protein coupled receptors
JP3873115B2 (ja) 2001-09-25 2007-01-24 独立行政法人産業技術総合研究所 環状ウレタン製造方法
JP4545437B2 (ja) 2001-10-15 2010-09-15 シェーリング コーポレイション アデノシンａ２ａ受容体アンタゴニストとしてのイミダゾ（４，３−ｅ）−１，２，４−トリアゾロ（１，５−ｃ）ピリミジン
RU2004118719A (ru) 2001-11-22 2005-03-27 Оно Фармасьютикал Ко., Лтд. (Jp) Производные пиперидин-2-она и фармацевтические композиции, содержащие такие соединения в качестве активного ингредиента
AU2002360818A1 (en) 2001-12-28 2003-07-24 Bayer Pharmaceuticals Corporation 1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
JP2003300884A (ja) 2002-04-08 2003-10-21 Nikken Chem Co Ltd ＴＮＦ−α産生阻害剤
AU2003216660A1 (en) 2002-04-26 2003-11-10 Pfizer Products Inc. N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
JP2005527598A (ja) 2002-04-26 2005-09-15 ファイザー・プロダクツ・インク トリアリール−オキシ−アリール−スピロ−ピリミジン−２，４，６−トリオンメタロプロテイナーゼ阻害剤
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
WO2003097608A2 (en) 2002-05-17 2003-11-27 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7041682B2 (en) 2002-07-03 2006-05-09 Schering Corporation NK1 antagonists
AU2003249812A1 (en) 2002-07-18 2004-02-09 Queen's University At Kingston Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents
GB0218630D0 (en) 2002-08-10 2002-09-18 Tanabe Seiyaku Co Novel compounds
AR041198A1 (es) 2002-10-11 2005-05-04 Otsuka Pharma Co Ltd Compuesto 2,3-dihidro-6-nitroimidazo[2,1-b] oxaxol, y composiciones farmaceuticas que lo contienen
AU2003302027A1 (en) 2002-11-21 2004-06-15 Vicore Pharma Ab New tricyclic angiotensin ii agonists
GB0228410D0 (en) 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
WO2004055008A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Compounds, compositions and methods
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
ATE474577T1 (de) 2003-03-26 2010-08-15 Merck Sharp & Dohme Bicyclische piperidin-derivate als melanocortin-4 rezeptor-agonisten
US7700583B2 (en) 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
DE602004027171D1 (de) 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
US7696198B2 (en) 2003-04-16 2010-04-13 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
ITMI20031292A1 (it) 2003-06-25 2004-12-26 Nikem Research Srl Derivati biciclici nk-2 antagonisti selettivi.
DE10358004A1 (de) 2003-12-11 2005-07-14 Abbott Gmbh & Co. Kg Ketolactam-Verbindungen und ihre Verwendung
US7186844B2 (en) 2004-01-13 2007-03-06 Mitsubishi Gas Chemical Co., Inc. Method for producing cyclic carbamate ester
JP4324669B2 (ja) 2004-01-21 2009-09-02 独立行政法人産業技術総合研究所 環状ウレタンの製造方法
JP2005239670A (ja) 2004-02-27 2005-09-08 Ono Pharmaceut Co Ltd 含窒素複素環化合物およびその医薬用途
EP1725535A4 (en) 2004-03-09 2009-11-25 Merck & Co Inc HIV integrase
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
EA011158B1 (ru) 2004-03-16 2009-02-27 Бёрингер Ингельхайм Интернациональ Гмбх Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения
JP2005272321A (ja) 2004-03-23 2005-10-06 Ono Pharmaceut Co Ltd 含窒素複素環化合物およびその医薬用途
CA2565630C (en) 2004-05-07 2013-05-28 Janssen Pharmaceutica N.V. Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
EP1747198B1 (en) 2004-05-07 2008-06-04 Janssen Pharmaceutica N.V. Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
GB0411404D0 (en) 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
AU2005247929B2 (en) 2004-05-24 2010-03-11 Amgen Inc. Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MXPA06014572A (es) 2004-06-24 2007-03-12 Incyte Corp Compuestos amido y su uso como farmaceuticos.
GB0414438D0 (en) 2004-06-28 2004-07-28 Syngenta Participations Ag Chemical compounds
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
EP1621535A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621539A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621536A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
MX2007001399A (es) 2004-08-02 2007-04-18 Osi Pharm Inc Compuestos que inhiben pirrolopirimidina multi-cinasa aril-amino sustituidas.
US7544677B2 (en) 2004-08-23 2009-06-09 Merck & Co., Inc. Inhibitors of Akt activity
CN101300005B (zh) 2004-08-30 2013-05-01 詹森药业有限公司 作为11-β羟类固醇脱氢酶抑制剂的N-2金刚烷基-2-苯氧基-乙酰胺衍生物
MY141198A (en) 2004-08-30 2010-03-31 Janssen Pharmaceutica Nv Tricyclic adamantylamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
CA2579514A1 (en) 2004-09-10 2006-03-23 Janssen Pharmaceutica N.V. Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (sarms)
EP1802623A1 (en) 2004-10-12 2007-07-04 Novo Nordisk A/S 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds
WO2006044174A2 (en) 2004-10-13 2006-04-27 Neurogen Corporation Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor
WO2006049952A1 (en) 2004-10-29 2006-05-11 Eli Lilly And Company Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
SG161261A1 (en) 2004-11-10 2010-05-27 Incyte Corp Lactam compounds and their use as pharmaceuticals
JP2008524162A (ja) 2004-12-16 2008-07-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンゼン誘導体、該化合物を含む薬物、その使用及びその製造方法
US20060167044A1 (en) 2004-12-20 2006-07-27 Arnaiz Damian O Piperidine derivatives and their use as anti-inflammatory agents
KR20070090915A (ko) 2004-12-23 2007-09-06 키에시 파르마슈티시 엣스. 피. 에이. 항 무스카린성 활성을 가진 아졸유도체
AU2005322085B2 (en) 2004-12-28 2012-07-19 Exelixis, Inc. [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
EP1838703A2 (en) 2005-01-19 2007-10-03 Neurogen Corporation Heteroaryl substituted piperazinyl-pyridine analogues
US7566718B2 (en) 2005-02-16 2009-07-28 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
AU2006214378A1 (en) 2005-02-16 2006-08-24 Pharmacopeia, Inc. Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
CA2598458A1 (en) 2005-02-16 2006-08-24 Schering Corporation Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity
CN101163692B (zh) 2005-02-16 2012-01-18 先灵公司 具有cxcr3拮抗活性的杂环取代的哌嗪
JP2008530216A (ja) 2005-02-16 2008-08-07 シェーリング コーポレイション Ｃｘｃｒ３アンタゴニスト活性を有する、複素環で置換された新規のピリジンまたはフェニル化合物
CN101189238A (zh) 2005-02-16 2008-05-28 先灵公司 具有cxcr3拮抗剂活性的哌嗪-哌啶
KR100890886B1 (ko) 2005-02-24 2009-03-31 니혼노야쿠가부시키가이샤 신규 할로알킬설폰아닐리드 유도체, 제초제 및 이의 이용방법
EP1864971A4 (en) 2005-03-31 2010-02-10 Takeda Pharmaceutical PROPHYLACTIC / THERAPEUTIC AGENT AGAINST DIABETES
WO2006109056A1 (en) 2005-04-12 2006-10-19 Vicore Pharma Ab New tricyclic angiotensin ii agonists
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007008529A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc Celullar cholesterol absorption modifiers
JP2009504769A (ja) 2005-08-16 2009-02-05 ジェンザイム・コーポレーション ケモカイン受容体結合化合物
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
EP1937666B1 (en) 2005-10-11 2012-02-22 Schering Corporation Substituted heterocyclic compounds with cxcr3 antagonist activity
US7943605B2 (en) 2005-10-27 2011-05-17 Ucb Pharma S.A. Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses
EA200801243A1 (ru) 2005-11-01 2008-10-30 Транстек Фарма Фармацевтическое применение замещенных амидов
JP2007140188A (ja) 2005-11-18 2007-06-07 Fujifilm Corp ポジ型感光性組成物及びそれを用いたパターン形成方法
US8541592B2 (en) 2005-11-22 2013-09-24 Amgen Inc. Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
EA200870019A1 (ru) 2005-12-05 2008-12-30 Инсайт Корпорейшн Лактамовые соединения и способы их применения
EP1801098A1 (en) 2005-12-16 2007-06-27 Merck Sante 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
WO2007076055A2 (en) 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
DE102005062990A1 (de) 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Thiazole und ihre Verwendung zur Herstellung von Arzneimitteln
WO2007081569A2 (en) 2005-12-30 2007-07-19 Merck & Co., Inc. Cetp inhibitors
US7781426B2 (en) 2005-12-30 2010-08-24 Merck Sharp & Dohme Corp. CETP inhibitors
US8865707B2 (en) 2005-12-30 2014-10-21 Merck Sharp & Dohme Corp. Cholesteryl ester transfer protein inhibitors
JP5040036B2 (ja) 2005-12-30 2012-10-03 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｅｔｐ阻害剤として有用な１，３−オキサゾリジン−２−オン誘導体
US7998959B2 (en) 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
AR059489A1 (es) 2006-02-15 2008-04-09 Boehringer Ingelheim Vetmed Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
RU2455925C2 (ru) 2006-02-27 2012-07-20 БАЙЕР ХЕЛТКЭА ЭлЭлСи Определение исследуемого вещества с поправкой на температуру для систем биодатчиков
WO2007101270A1 (en) 2006-03-02 2007-09-07 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
US20070208001A1 (en) 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2007109456A2 (en) 2006-03-16 2007-09-27 Pharmacopeia, Inc. Substituted biphenyl isoxazole sulfonamides as dual angiotensin endothelin receptor antagonists
JP2007254409A (ja) 2006-03-24 2007-10-04 Taisho Pharmaceut Co Ltd イミダゾリジノン誘導体
US7435833B2 (en) 2006-04-07 2008-10-14 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
BRPI0710380A2 (pt) 2006-04-20 2011-08-09 Du Pont composto, composição, composição de controle de pragas, invertebradas, de pulverização, de isca, dispositivo de armadilha, métodos de controle, métodos de proteção, semente tratada e composição de proteção
NZ571175A (en) 2006-04-21 2011-10-28 Lilly Co Eli Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US8088776B2 (en) 2006-04-21 2012-01-03 Eli Lilly And Company Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
BRPI0710273A2 (pt) 2006-04-21 2011-08-09 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, intermediário
CA2649650C (en) 2006-04-24 2014-01-14 Eli Lilly And Company Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US7968585B2 (en) 2006-04-25 2011-06-28 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US8178005B2 (en) 2006-06-20 2012-05-15 Chemtura Corporation Liquid phosphite compositions having different alkyl groups
TW200811170A (en) 2006-06-27 2008-03-01 Sanofi Aventis Urea derivatives of tropane, their preparation and their therapeutic application
WO2008012622A2 (en) 2006-07-25 2008-01-31 Pfizer Products Inc. Azabenzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
WO2008012623A1 (en) 2006-07-25 2008-01-31 Pfizer Products Inc. Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
US7618989B2 (en) 2006-08-15 2009-11-17 Wyeth Tricyclic oxazolidone derivatives useful as PR modulators
WO2008021337A1 (en) 2006-08-15 2008-02-21 Wyeth Oxazinan-2-one derivatives useful as pr modulators
CA2656847A1 (en) 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
US7649007B2 (en) 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
EP2064187A2 (en) 2006-08-25 2009-06-03 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
CA2663280A1 (en) 2006-09-14 2008-03-20 Neuromed Pharmaceuticals Ltd. Diaryl piperidine compounds as calcium channel blockers
MX2009003080A (es) 2006-09-22 2009-04-02 Novartis Ag Compuestos organicos heterociclicos.
DE102007005799B4 (de) 2006-10-18 2018-01-25 Heinz-Jürgen Mühlen Verfahren zur Erzeugung eines wasserstoffreichen Produktgases
AU2007312391B2 (en) 2006-10-19 2012-06-21 F. Hoffmann-La Roche Ag Imidazolone and imidazolidinone derivatives as 11b-HSD1 inhibitors for diabetes
AR063569A1 (es) 2006-11-06 2009-02-04 Boehringer Ingelheim Int Derivados de benzil- benzonitrilo sustituidos con glucopiranosilo medicamentos que contienen a compuestos de este tipo su uso u procedimiento para su fabricacion
TW200829171A (en) 2006-11-17 2008-07-16 Nihon Nohyaku Co Ltd Haloalkyl sulfonanilide derivatives or salts thereof, herbicide using it as effective constituent and use-method thereof
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
US8835426B2 (en) 2007-02-26 2014-09-16 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1
EP2139911A2 (en) 2007-03-23 2010-01-06 Schering Corporation Hydrazido-peptides as inhibitors of hcv ns3-protease
BRPI0809646A2 (pt) 2007-03-29 2014-09-23 Hoffmann La Roche Compostod antivirais heterocíclicos
JP5451611B2 (ja) 2007-07-26 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックインヒビター
WO2009020140A1 (ja) 2007-08-06 2009-02-12 Dainippon Sumitomo Pharma Co., Ltd. アダマンチルウレア誘導体
JP2009110842A (ja) 2007-10-31 2009-05-21 Sumitomo Chemical Co Ltd ボタンスイッチ被覆用積層樹脂体
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
US8859580B2 (en) 2007-11-16 2014-10-14 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
CA2708303A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
KR101460359B1 (ko) 2007-12-13 2014-11-10 삼성전자주식회사 이동통신 시스템에서의 핸드오버 방법 및 장치
TW200934490A (en) 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
WO2009094169A1 (en) 2008-01-24 2009-07-30 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2714532A1 (en) 2008-02-11 2009-08-20 Vitae Pharmaceuticals, Inc. 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
CA2711757C (en) 2008-02-12 2016-07-26 Boehringer Ingelheim International Gmbh Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
US8598160B2 (en) 2008-02-15 2013-12-03 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
JP5108557B2 (ja) 2008-02-27 2012-12-26 東京エレクトロン株式会社 ロードロック装置および基板冷却方法
EP2265588B1 (en) 2008-02-27 2013-06-26 Vitae Pharmaceuticals, Inc. INHIBITORS OF 11ß -HYDROXYSTEROID DEHYDROGENASE TYPE 1
CA2718264A1 (en) 2008-03-18 2009-09-24 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
TW200944526A (en) 2008-04-22 2009-11-01 Vitae Pharmaceuticals Inc Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
CA2723032A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2291370B1 (en) 2008-05-01 2013-11-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
KR20110002492A (ko) 2008-05-01 2011-01-07 비타이 파마슈티컬즈, 인코포레이티드 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
TW201004945A (en) 2008-05-01 2010-02-01 Vitae Pharmaceuticals Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8765780B2 (en) 2008-05-13 2014-07-01 Boehringer Ingelheim International Gmbh Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
WO2010010149A1 (en) 2008-07-23 2010-01-28 Bioalliance Pharma Styrylquinolines, their process of preparation and their therapeutic uses
US20110224242A1 (en) 2008-07-23 2011-09-15 Bioalliance Pharma Styrlyquinolines, their process of preparation and their therapeutic uses
CA2729993A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
CA2730208C (en) 2008-07-25 2016-10-25 Boehringer Ingelheim International Gmbh 1,1'-diadamantyl carboxylic acids, medicaments containing such compounds and their use
US8846668B2 (en) 2008-07-25 2014-09-30 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2010011314A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
CA2735204C (en) 2008-08-25 2017-06-20 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use
CA2738453C (en) 2008-10-23 2017-07-04 Boehringer Ingelheim International Gmbh Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
US8598163B2 (en) 2009-02-04 2013-12-03 Vitae Pharmaceuticals, Inc. Derivatives of [1,3]Oxazin-2-one useful for the treatment of metabolic diseases such as lipid disorders
JP5679997B2 (ja) 2009-02-04 2015-03-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
US8563583B2 (en) 2009-03-09 2013-10-22 Bristol-Myers Squibb Company Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
KR20120061771A (ko) 2009-04-30 2012-06-13 비타이 파마슈티컬즈, 인코포레이티드 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
UA109255C2 (ru) * 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
AR076936A1 (es) 2009-06-02 2011-07-20 Vitae Pharmaceuticals Inc Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1
US8703765B2 (en) 2009-06-02 2014-04-22 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
WO2011011123A1 (en) 2009-06-11 2011-01-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
WO2011002910A1 (en) 2009-07-01 2011-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
MX2012002994A (es) 2009-09-11 2012-07-17 Cylene Pharmaceuticals Inc Lactamas heterociclo-substituidas farmaceuticamente utiles.
EP2496589B1 (en) 2009-11-05 2014-03-05 Boehringer Ingelheim International GmbH Novel chiral phosphorus ligands
AR078887A1 (es) 2009-11-06 2011-12-07 Boehringer Ingelheim Int Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina y composiciones farmaceuticas que los contienen.
EP2582698B1 (en) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
WO2011161128A1 (en) 2010-06-25 2011-12-29 Boehringer Ingelheim International Gmbh Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
CA2813671A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders

Also Published As

Publication number Publication date
EA201300522A1 (ru) 2013-11-29
PH12013500808A1 (en) 2015-10-07
US20130225566A1 (en) 2013-08-29
BR112013010021A2 (pt) 2019-09-24
TW201304783A (zh) 2013-02-01
CN103179960A (zh) 2013-06-26
EP2635268A1 (en) 2013-09-11
KR20130137628A (ko) 2013-12-17
US20120277149A1 (en) 2012-11-01
UY33700A (es) 2012-06-29
AR083679A1 (es) 2013-03-13
US8846613B2 (en) 2014-09-30
AU2011325286A1 (en) 2013-02-28
WO2012059416A1 (en) 2012-05-10
AU2011325286B2 (en) 2015-04-16
MX2013004699A (es) 2013-05-22
US20140038888A1 (en) 2014-02-06
JP2013540801A (ja) 2013-11-07
CA2813671A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
CL2008001271A1 (es) Compuestos derivados de heterociclos de nitrogeno y oxigeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, hiperglicemia, intolerancia a la glucosa, aterosclerosis, dislipidemia, obesid
CL2007002197A1 (es) Compuestos derivados de indol; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes mellitus, retinopatia diabetica, hiperglucemia, hiperl
CL2008000133A1 (es) Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido combinado con al menos un segundo agente terapeutico; y uso de la composicion para el tratamiento de diabetes mellitus, cataratas, neuropatia, infarto de miocardio, e
CL2007002296A1 (es) Compuestos derivados de imidazolina-2,4-dionas sustituidas con arilaminoalquilo; composicion farmaceutica; y uso del compuesto en el tratamiento del sindrome metabolico, diabetes, obesidad, dependencia de la nicotina, dependencia del alcohol, trastor
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
CL2007003614A1 (es) Compuestos derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos del metabolismo, como diabetes mellitus, dis
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI1007018A2 (pt) composto, composição farmacêutica, e , uso de um composto.
CL2007002018A1 (es) Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
CL2013000685A1 (es) Compuestos derivados de n-(fenil/bencil)-6-(1,2,4-oxadiazol-3-il)-1,3,5-triazin-2,4-diamina; bloqueadores de los canales de sodio ( nav 1.7); composicion farmaceutica; que los comprende; uso en el tratamiento del dolor cronico.
CL2008001049A1 (es) Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad.
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
BRPI1008906A2 (pt) composto, composição farmacêutica, e, uso de um composto.
CL2014001437A1 (es) Compuestos derivados de aril dihidropiridinona y piperidinona como inhibidores de monoacilglicerol aciltransferasa (mgat2); composicion y combinacion farmaceutica; y uso en el tratamiento y prevencion de diabetes, hiperglucemia, retinopatia, sindrome metabolico, entre otras enfermedades.
CL2007002610A1 (es) Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0813680A2 (pt) AGENTES DE iRNA, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS MESMOS, BEM COMO SEU USO.
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина